Skip to Content

Sylvant Approval History

FDA Approved: Yes (First approved April 22, 2014)
Brand name: Sylvant
Generic name: siltuximab
Dosage form: for Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multicentric Castleman's Disease

Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.

Development History and FDA Approval Process for Sylvant

DateArticle
Apr 23, 2014Approval FDA Approves Sylvant for Multicentric Castleman’s Disease
Sep  3, 2013Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide